[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"apatinib\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:apatinib":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100553390","phase-3-tace-plus-camrelizumab-and-apatinib-for-unresectable-hepatocellular-carcinoma-100553390",false,"NCT06485466","TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","Transarterial Chemoembolization Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma : a Randomised , Open Label, Multicenter Controlled Trial","Inclusion Criteria:\n\n1. Histopathologically or clinically confirmed hepatocellular carcinoma\n2. 18-80 years old.\n3. Performance status (PS) ≤ 1 (ECOG scale).\n4. Barcelona clinical liver cancer (BCLC) stage B or stage C.\n5. Initial treatment of hepatocellular carcinoma.\n6. According to mRECIST, there is at least one measurable lesion.\n7. Child Pugh score ≤ 7.\n8. Participant has sufficient organ and marrow functions.\n9. Expected survival time ≥ 12 weeks.\n10. For women of childbearing age or male patients whose sexual partners are women of childbearing age, effective contraceptive measures should be taken during the whole treatment period and 6 months after the last medication.\n11. Sign the written informed consent, and be able to follow the visit and relevant procedures specified in the plan.\n\nExclusion Criteria:\n\n1. Fibrolamellar carcinoma, sarcomatoid carcinoma, cholangiocarcinoma and other components previously confirmed by histology \u002F cytology.\n2. History of hepatic encephalopathy or liver transplantation.\n3. Pleural effusion, ascites and pericardial effusion with clinical symptoms requiring drainage.\n4. Tumor burden≥70%, diffuse liver cancer or tumor is not suitable for mRECIST standard evaluation.\n5. Received local treatment (ablation therapy, TACE), surgery resection and radiotherapy for liver cancer before the first administration.\n6. Have received systemic chemotherapy, targeted therapy or immunotherapy\n7. There is a significant decrease in white blood cells and platelets in peripheral blood, severe coagulation dysfunction and can not be corrected：the neutrophil\\\u003C1.5×109\u002FL, PLT\\\u003C50×109\u002FL. The INR\\>2.3\n8. Acute or chronic active hepatitis B or C infection, hepatitis B virus (HBV-DNA) \\> 10\\^6 copies \u002F ml; hepatitis C virus (HCV-RNA) \\> 10\\^3 copies \u002F ml; HBsAg and anti HCV antibody were positive at the same time.\n9. There is central nervous system metastasis.\n10. Bleeding of esophageal or gastric varices caused by portal hypertension occurred in the past 6 months, or severe (G3) varices were found in endoscopic examination within 3 months before the first administration, or evidence of portal hypertension (including splenomegaly found in imaging examination) was found. The researchers assessed that the risk of bleeding was high and did not receive sclerotherapy or ligation under the endoscope.\n11. The previous 6-month history of arteriovenous thromboembolism, including myocardial infarction, unstable angina, cerebrovascular accident, pulmonary embolism, deep vein thrombosis or any other serious thromboembolism. The thrombus of implanted vein port or catheter source or superficial vein is stable after routine anticoagulant treatment. Prophylactic use of low-molecular-weight heparin (e.g., enoxaparin 40 mg \u002F day) is permitted.\n12. Tumor thrombus of main portal vein, or involving superior mesenteric vein at the same time.\n13. Aspirin (\\> 325 mg \u002F day) or other drugs known to inhibit platelet function such as dipyridamole or clopidogrel were used for 7 consecutive days within 2 weeks before the first administration.\n14. For uncontrolled hypertension, systolic blood pressure \\> 150 mmHg or diastolic blood pressure \\> 100 mmHg after the best medical treatment, hypertension crisis or hypertension encephalopathy history.\n15. Symptomatic congestive heart failure (New York Heart Association class II-IV). Symptomatic or poorly controlled arrhythmias. The corrected QT interval (QTc) for the history or screening of congenital long QT syndrome was more than 500 ms (calculated by Fridericia method).\n16. Serious bleeding tendency or coagulation dysfunction, or undergoing thrombolysis.\n17. In the past 6 months, there was a history of gastrointestinal perforation and \u002F or fistula, a history of intestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive enterotomy (partial colectomy or extensive enterotomy with chronic diarrhea), Crohn's disease, ulcerative colitis or long-term chronic diarrhea.\n18. Previous and current pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, severe impairment of lung function and other lung diseases.\n19. Active tuberculosis (TB), who is receiving anti TB treatment or has received anti TB treatment within one year before the first administration.\n20. People with HIV infection (HIV 1 \u002F 2 antibody positive) and known syphilis infection. Serious infection in active stage or poor clinical control.\n21. Severe infection within 4 weeks before the first administration, including but not limited to hospitalization due to complications of infection, bacteremia or severe pneumonia.\n22. Active autoimmune diseases requiring systemic treatment (such as the use of disease alleviation drugs, corticosteroids or immunosuppressants) occurred within 2 years before the first administration. Alternative therapies (e.g. thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are permitted. Known history of primary immunodeficiency. Only the patients with positive autoimmune antibody need to confirm whether there is autoimmune disease according to the judgment of researchers.\n23. Immunosuppressive drugs were used within 4 weeks before the first administration, excluding local glucocorticoids or systemic glucocorticoids (i.e.\n\n    no more than 10 Mg \u002F day prednisone or the equivalent dose of other glucocorticoids), allowing temporary use of glucocorticoids due to dyspnea symptoms in the treatment of asthma, chronic obstructive pulmonary disease and other diseases.\n24. Receive live attenuated vaccine within 4 weeks before the first administration or during the study period.\n25. Major surgical procedures (craniotomy, thoracotomy or open hand) were performed within 4 weeks before the first administration (surgery) or an unhealed wound, ulcer, or fracture.\n26. Uncontrolled \u002F uncorrectable metabolic disorder or other non- malignant organ disease or systemic disease or cancer secondary reaction, which may lead to higher medical risk and \u002F or uncertainty of survival evaluation.\n27. Known to be allergic to any PD-1 monoclonal antibody component.\n28. Women of childbearing age who are unwilling or unable to use acceptable methods of contraception during the whole treatment period of this trial and within 12 weeks after the last administration of the study drug (women of childbearing age include: any women who have had menarche, and have not undergone successful artificial sterilization (hysterectomy, bilateral tubal ligation, or bilateral ovariectomy), pregnancy or lactation Women; women with positive pregnancy test results at the time of inclusion or before study drug administration; If the partner is a woman of childbearing age, the subject is a fertile male without effective contraceptive measures.","ALL","18 Years","80 Years",{"count":20,"type":21},101,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death worldwide. The majority of patients with HCC are diagnosed as intermediate or advanced stage disease, and not eligible for curative treatments including transplantation, resection, and ablation. Transarterial chemoembolization (TACE) is recommended as first-line treatment for patients with intermediate-stage HCC, while it is also widely used in the unresectable HCC.\n\nThe clinical efficacy and safety in advanced HCC patients of camrelizumab plus apatinib were reported in phase 3 trial (CARES-310). Camrelizumab plus apatinib with a median progression-free survival of 5.7 months and a median overall survival of 22.1 months in advanced HCC.\n\nThis study is randomized, open-label, multicenter controlled trial; which was focused in initial BCLC-B\u002FC HCC patients. This study aimed to compare the efficacy and safety of TACE plus programmed death-1 inhibitor (camrelizumab), and anti-angiogenic therapy (apatinib) with camrelizumab plus apatinib.",[27,28,29,30],"Unresectable Hepatocellular Carcinoma","Transarterial Chemoembolization","Camrelizumab","Apatinib","RECRUITING","2026-04-12",{"date":34,"type":35},"2026-04-14","ACTUAL",{"date":37,"type":35},"2024-08-10",{"date":39,"type":21},"2028-06-30",{"name":41,"class":42},"Guohui Xu","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100595338","phase-2-a-single-arm-multicenter-prospective-clinical-study-of-adebrelimab-combined-with-apatinib-neoadjuvant-therapy-for-resectable-non-small-cell-lung-cancer-100595338","NCT07031154","A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Participants must meet all of the following criteria to be enrolled in the study:\n* 18 years old ≤ age ≤70 years old, male or female;\n* ECOG PS score 0-1;\n* Patients who have not received systematic treatment before and agree to receive radical surgical treatment; Thoracic surgeons judge patients with no contraindications to surgery;\n* Stage II, IIIA, or selective stage IIIB (T3N2M0 only) squamous cell or non-squamous non-small cell lung cancer confirmed by histopathology or cytology and determined by the investigator to be capable of R0 resection for curative purposes. Staging should be based on the American Joint Committee on Cancer (AJCC)\u002FUnion International Against Cancer (UICC) NSCLC Staging System Version 8;\n\n  1. Not allowed to invade the heart, great blood vessels, trachea, recurrent laryngeal nerve, esophagus, vertebrae, protuberances,And T4 tumors with dispersed tumor nodules in different lung lobes on the same side;\n  2. Upper lung groove cancer is not allowed;N2 was defined as mediastinal lymph node non-giant metastases (lymph node diameter \\\u003C 2cm) confirmed by imaging or pathology and expected to be completely resectable.\n* There were enough tumor tissues to detect PD-L1 expression and PD-L1 ≥1%;\n* At least one measurable lesion (according to RECIST 1.1 criteria);\n* Expected survival of at least 12 weeks;\n* Other major organs (liver, kidney, blood system, etc.) function well:\n\n  1. Hemoglobin ≥90g\u002FL (no blood transfusion, no hematopoietic factors, and no drug correction within 2 weeks prior to the first dose);Absolute neutrophil count (ANC) ≥1.5×109\u002FL;\n  2. Platelet count ≥100×109\u002FL;\n  3. Total bilirubin ≤1.5 times the upper limit of normal value;\n  4. Alanine aminotransferase, ASpartate aminotransferase, alkaline phosphatase ≤2.5 times the upper limit of normal value;\n  5. Serum creatinine ≤1.5 times the upper limit of normal value; And endogenous creatinine clearance ≥60ml\u002Fmin;\n  6. International Standardized Ratio of prothrombin time (INR)≤1.5 and activated partial thromboplastin time (APTT)≤1.5 times the upper limit of normal for patients who have not received anticoagulant therapy.\n* No systemic metastasis (including M1a, M1b, M1c);\n* Complete excision is expected;\n* Lung function is good and can tolerate surgical treatment;\n* Fertile female subjects must have a negative pregnancy test (serum or urine) within 3 days prior to the start of the study drug, and be willing to use a medically approved highly effective contraceptive during the study period and 90 days after the last study drug administration(e.g. intrauterine devices, contraceptives, or condoms); Male subjects whose partner is a woman of reproductive age must consent to use effective contraception or have been surgically sterilized during the study period and 90 days after the last study dosing;\n* Subjects voluntarily participate in this clinical study and sign informed consent.\n\nExclusion Criteria:\n\n* Subjects will not be admitted to the study if they have any of the following conditions:\n* have received any anti-tumor therapy in the past, including radiotherapy, chemotherapy, immunotherapy and traditional Chinese medicine anti-tumor therapy (except the treatment of malignant tumors with radical treatment and no recurrence and metastasis for more than 5 years);\n* Subjects with non-squamous cell histological types of NSCLC with EGFR mutation positive or ALK positive. Non-squamous cell carcinoma subjects must undergo EGFR gene testing and ALK gene and\u002For immunohistochemical testing;\n* Patients with distant metastases (including M1a, M1b, and M1c);\n* Have any active autoimmune disease or history of autoimmune disease (such as uveitis, enteritis, hepatitis, pituitaritis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (may be included after hormone replacement therapy), tuberculosis); Skin conditions (such as vitiligo, psoriasis, or alopecia) with complete remission of childhood asthma that do not require any intervention in adulthood and do not require systemic treatment may be included, but patients requiring medical intervention with bronchodilators may not be included;\n* Exclude evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiological pneumonia, drug-induced pneumonia, radiographic evidence of active pneumonia, and severe impairment of lung function;\n* Subjects who have received systemic treatment with corticosteroids (\\>10 mg\u002F day of prednisone or other equivalent hormones) or other immunosuppressants within 2 weeks prior to initial dosing. In the absence of active autoimmune disease, inhaled or topical corticosteroids are permitted, as well as adrenal hormone replacement therapy at doses ≤10 mg\u002F day of prednisone efficacy;\n* Imaging (CT or MRI) shows that the tumor has invaded large blood vessels or the boundary with blood vessels is blurred; Or imaging (CT or MRI) showing the presence of any pulmonary cavities or necrotic lesions, as determined by the investigator;\n* Patients who had experienced arteriovenous thrombosis events, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism within 6 months before enrollment;\n* Had clinically significant bleeding symptoms or definite bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, etc., or were receiving thrombolytic or anticoagulant therapy within 3 months before enrollment;\n* Obvious symptoms of hemoptysis or daily hemoptysis volume of 2.5mL or more within 1 month before enrollment;\n* Patients with hypertension who are not well controlled by antihypertensive drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); Or grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450ms in men and women)≥470ms); According to NYHA criteria, patients with grade Ⅲ to Ⅳ cardiac insufficiency or left ventricular ejection fraction (LVEF) \\\u003C 50% indicated by cardiac color ultrasound;\n* Major operations or serious external injuries of other systems were performed within 2 months before the start of the study;\n* Urine routine indicated urinary protein ≥(++), or 24h urinary protein ≥1g or severe hepatic and renal insufficiency;\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;\n* Allergic to the experimental drug;\n* Co-existing with HIV infection or active viral hepatitis;\n* Pregnant or lactating women; The fertile subject is unwilling or unable to take effective contraceptive measures;\n* Those who suffer from neurological diseases or mental diseases and cannot cooperate;\n* Other malignancies developed within 5 or less years before admission, excluding adequately treatable cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery;\n* Other situations deemed unsuitable for inclusion by the researcher.","70 Years",{"count":52,"type":21},43,[54],"PHASE2","To evaluate the major pathological response rate of Adibelimab combined with Apatinib neoadjuvant therapy in resectable non-small cell lung cancer.",[57,58,30],"Non-Small Cell Lung Cancer","Adebrelimab","NOT_YET_RECRUITING","2025-06-12",{"date":62,"type":35},"2025-06-22",{"date":64,"type":21},"2025-06-30",{"date":66,"type":21},"2027-02-01",{"name":68,"class":42},"The First Affiliated Hospital of Xiamen University",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":43},"100478631","phase-2-camrelizumab-plus-apatinib-and-temozolomide-as-neoadjuvant-in-high-risk-acral-melanoma-100478631","NCT05512481","Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma","A Phase 2 Clinical Trial of Neoadjuvant Camrelizumab Plus Apatinib and Temozolomide in High Risk Clinical Stage Ⅱ-Ⅲ Acral Melanoma","Inclusion Criteria:\n\n1. age:18-75 years, male or female.\n2. Histopathologically confirmed acral melanoma (stage Ⅱ\u002FⅢ).\n3. Has not received any systematic anti-tumor drug treatment.\n4. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.\n5. ECOG 0-1.\n6. Adequate organ function.\n7. Life expectancy of greater than 12 weeks.\n8. Patient has given written informed consent.\n\nExclusion Criteria:\n\n1. Patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy.\n2. Known history of hypersensitivity to any component of apatinib, temozolomide, Camrelizumab.\n3. Subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ);\n4. Subjects with any active autoimmune disease or history of autoimmune disease\n5. Patients with any unstable systemic disease, including but not limited to: serious infection, uncontrolled diabetes, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, myocardial infarction, congestive heart failure, serious cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease;\n6. Received a live vaccine within 4 weeks of the first dose of study medication.\n7. Pregnancy or breast feeding.\n8. Decision of unsuitableness by principal investigator or physician-in charge.","75 Years",{"count":78,"type":21},60,[54],"Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.",[82,83,84,30,29,85,86],"Melanoma","Acral Melanoma","Temozolomide","Neoadjuvant","Pathological Response",[83,88,89,90],"Immune Checkpoint Inhibitors","Protein Kinase Inhibitors","Antineoplastic Agents, Alkylating","2025-02-28",{"date":93,"type":35},"2025-03-03",{"date":95,"type":35},"2022-09-13",{"date":97,"type":21},"2026-12-31",{"name":99,"class":42},"Peking University Cancer Hospital & Institute"]